A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Focal Epilepsy
Interventions
DRUG

Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide

"* Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d"

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00855738 - A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice | Biotech Hunter | Biotech Hunter